Last updated:
Author(s):
Mahdi Sheikh, Allison Domingues, Karine Alcala, Ryan Langdon, Daniela Mariosa, Xiaoshuang Feng, Peter Sarich, Marianne F Weber, Vivian Viallon, Agnes Fournier, Farin Kamangar, Reza Malekzadeh, Chris Gillette, Mara Z Vitolins, Meredith C B Adams, Shama Virani, Elmira Ebrahimi, Tom Dudding, Tessel E Galesloot, Lambertus A Kiemeney, Nathaniel Rothman, Stella Koutros, Jifang Zhou, Sallie-Anne Pearson, Marie-Odile Parat, Paul Brennan, Mattias Johansson, George Davey Smith, Hilary A Robbins
Publish date:
11 November 2025
Journal:
EClinicalMedicine
PubMed ID:
41357337

Abstract

Background: Opium consumption was classified as “carcinogenic to humans” by the International Agency for Research on Cancer (IARC). We investigated whether use of pharmaceutical opioids, derived from or synthesized to mimic opium, is associated with cancer risk using separate observational and genetic analyses.

Methods: Observational analysis included 472,955 participants in the UK Biobank prospective cohort (2006-2022). Genetic analysis included 2-sample Mendelian Randomization (MR) analyses using data from 14 independent genome-wide-association-studies (N = 9931-357,292). Adjusted hazard ratios (a-HR) or odds ratios (ORs) associated with regular opioid use were assessed for six established opium-related cancers (lung, pancreatic, bladder, esophageal, oropharyngeal, and laryngeal) and seven non-opium-related cancers (prostate, breast, colon, endometrial, kidney, ovarian, and brain).

Findings: In UK Biobank, regular opioid use was associated with increased risk of opium-related cancers among ever-smoking [a-HR = 1.33 (95% CI = 1.22-1.43)] and never-smoking participants [a-HR = 1.32 (1.10-1.59)], but not non-opium-related cancers [a-HR = 0.96 (0.91-1.02)]. Risk increased with opioid strength [a-HR = 1.30 (1.20-1.40) for weak opioids; a-HR = 1.86 (1.43-2.40) for strong opioids, p-trend < 0.0001] and duration of action [a-HR = 1.32 (1.22-1.42) for short-acting; a-HR = 1.65 (1.24-2.18) for long-acting opioids, p-trend < 0.0001]. Both observational and genetic analyses showed increased risks for most opium-related cancers, including lung [a-HR = 1.39 (1.27-1.53); MR-Odds Ratio (OR) = 1.17 (1.07-1.29)], pancreas [a-HR = 1.24 (1.01-1.52); MR-OR = 1.34 (1.11-1.62)], bladder [a-HR = 1.26 (1.02-1.56); MR-OR = 1.15 (1.03-1.29)], esophagus [a-HR = 1.18 (0.94-1.49); MR-OR = 1.24 (1.01-1.52)], and larynx [a-HR = 1.37 (0.85-2.20); MR-OR = 1.29 (1.04-1.61)]. Except for an inverse association with prostate cancer [a-HR = 0.83 (0.76-0.91); MR-OR = 0.99 (0.92-1.05)], associations were null for non-opium-related cancers.

Interpretation: Regular use of pharmaceutical opioids was associated with elevated risk for cancers caused by opium, but not other cancers.

Funding: US National Institutes of Health, French National Cancer Institute.

Related projects

* Scientific rationale: The specialized cancer agency of the World Health Organization (IARC) has recently recognized the use of opium (opioids’ natural source) as…

Institution:
International Agency for Research on Cancer, France

All projects